FDA Inspection
Boehringer Ingelheim Biopharmaceuticals (China) Ltd.Boehringer Ingelheim Biopharmaceuticals (China) Ltd. – FDA Inspection, Jul 24, 2026
Record Details
This FDA Inspection record concerns Boehringer Ingelheim Biopharmaceuticals (China) Ltd., with an inspection on July 24, 2026, issued by the Office of Inspections and Investigations, covering human drugs.
- Inspection Date
- July 24, 2026
- Product Type
- Human Drugs
View Company Profile
ID · 0ce26aa4-613f-4fcb-be37-03eb4ca234cd
Inspection Facts
- Inspection number
- 1330776
- FDA center
- Human Drugs
- Outcome
- Form 483 issued
Other FDA inspections of Boehringer Ingelheim Biopharmaceuticals (China) Ltd.
1| Date | Classification | Office | Project area |
|---|---|---|---|
| June 9, 2023 | Not classified | Office of Inspections and Investigations |
Other documents for Boehringer Ingelheim Biopharmaceuticals (China) Ltd.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.